ANALYSIS OF TROPONIN I IN CATS WITH HCMP AND CHF ON THE BACKGROUND OF COMPLEX THERAPY

Abstract

The study evaluates the role of cardiospecific troponin I as a marker of myocardial damage in cats with primary hypertrophic cardiomyopathy and congestive heart failure, as well as the effect of complex therapy including drug treatment and dietary correction on the dynamics of the biomarker. The work was performed on 60 cats with echocardiographically confirmed cardiomyopathy, divided into two therapeutic groups of 30 animals each, as well as a control group of 30 healthy cats; The level of troponin I was determined before the start of therapy and after 3-6 months of treatment, comparing the average values and the distribution into categories "normal or close to normal" (<0.06 ng/ml), "moderate" and "significant" increase (≥0.21 ng/ml). Basic drug therapy caused a moderate decrease in troponin I and partial normalization of the profile, however, a significant proportion of animals retained the marker above the reference range. The addition of a specialized cardiological diet to the treatment regimen led to a more pronounced decrease in the average values of the marker, an increase in the proportion of cats with normal and near-normal results, and a decrease in the proportion of animals with a marked increase in troponin I. The data obtained substantiate the expediency of combining dietary correction with drug treatment as a way to reduce chronic myocardial damage and potentially improve prognosis in cats with congestive heart failure on the background of hypertrophic cardiomyopathy, while the limited sample size and short follow-up period require confirmation of the results in larger randomized trials.